A Multimodal Approach to Open-Angle Glaucoma with Travoprost Intracameral Implant and Minimally Invasive Glaucoma Surgery with or Without Concurrent Cataract Surgery
Abstract
Introduction: This study aimed to characterize reductions in intraocular pressure (IOP) and the need for topical IOP-lowering medications in eyes undergoing implantation of a travoprost implant (iDose TR®; Glaukos) and either trabecular micro-bypass stent (iStent infinite®; Glaukos) implant or canaloplasty with or without cataract surgery in eyes with open-angle glaucoma (OAG).
Methods: Adults undergoing the procedures of interest with ≥ 3 months of postoperative follow-up were included. The primary outcomes were changes in mean IOP and topical medication use from baseline to 3 months postoperatively. Analyses were conducted in the overall cohort and stratified by surgical context (with and without concurrent cataract surgery) and minimally invasive glaucoma surgery (MIGS) modality (iStent infinite and canaloplasty), resulting in four subgroups: iDose TR + iStent infinite with phacoemulsification, iDose TR + iStent infinite, iDose TR + canaloplasty with phacoemulsification, and iDose TR + canaloplasty.
Results: Data from 107 eyes were analyzed. Overall, mean (standard deviation) IOP decreased from 19.0 (5.9) mmHg at baseline to 15.3 (4.6) mmHg at month 3 (p < 0.0001). In the phaco+ subgroup (66 eyes), mean IOP decreased from 17.5 (4.0) mmHg at baseline to 14.3 (2.4) mmHg (p < 0.0001) at month 3; in the phaco- subgroup, (41 eyes), mean IOP decreased from 21.6 (7.6) mmHg at baseline to 16.8 (6.5) mmHg (p = 0.001) at month 3. At month 3, topical medication-free rates were 59.4%…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.